Baxalta collaborates with Precision BioSciences on CAR T cell therapies

USA biotech firm Baxalta (NYSE: BXLT) has entered into a collaboration with genome editing company Precision BioSciences to develop a series of allogeneic chimeric antigen receptor (CAR) T cell therapies for a range of cancers, it has been announced.

CAR T is widely recognized as a breakthrough technology with the potential to become a curative option for certain malignancies.

David Meek, executive vice president of Baxalta, said: “Collaborating with Precision BioSciences enables Baxalta to accelerate innovation in immune-oncology with a next-generation, donor-derived CAR T strategy using a proprietary combination of genome editing expertise and technology enables the production of CAR T cells derived from healthy donors rather than relying on the patient.”